Physician profile
Wesley K Young
NPI 1053365700
$2,575.97
in general payments reported to CMS, 2019-2025
14 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $165 · 2021: $75.58 · 2022: $257 · 2023: $821 · 2024: $754 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.37 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $981.02 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $749.07 | 2023-2025 | |
| Horizon Therapeutics Plc | $184.98 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $138.82 | 2022-2024 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $126.34 | 2022-2024 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $118.97 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $64.20 | 2023-2024 | Rybelsus, Ozempic |
| Amgen INC. | $50.44 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Amarin Pharma, INC. | $34.22 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $33.87 | 2020 | |
| Novartis Pharmaceuticals Corporation | $33.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.30 | 2024 | Camzyos |
| Abbvie INC. | $23.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.